To be exact, Zytiga sales were up 35.1% yoy in the US and 48% in overseas markets. The prechemo indication is obviously helping them. The fact that the recent quarter's sales would indicate annual sales of at least $2.25 billion gives us some idea of how strong Xtandi sales can be behind a prechemo indication. Incidentally, JNJ is also down about 5 points since they reported earnings.
We've lost 5 points since JNJ reported earnings on July 11. I'll speculate that the relatively strong Zytiga sales reported may be causing some to extrapolate weaker Xtandi uptake. I'd note that most of the increase in Zytiga sales was in overseas markets and that I think it's been established that Xtandi is taking share from Zytiga. A larger share of a growing market would seem to be good news to me.
Any idea why this stock is having any downward pressure? They are 2 months out from receiving approval to have drug treat pre chemotherapeutic prostate cancer which will push sales over $2 Billion. Xtandi beat JNJ drug Zytiga on every metric in the clinical trial in these patients.
Can't believe this company still sitting in the $70's with pre-chemotherapy indication only a matter of months away. Drug already close to $1 Billion/year sales and that will double fast with expanded label.
A simple reply to your simple post. Xtandi was approved nearly two years ago and MDVN is still not showing a profit regardless of the price. The cost to find, test, go thru lenghty FDA approval (and have no guarantees youll ever get approved) produce and market a drug is staggering. If there is no hope of earning an eventual profit companies would simply stop experimenting. It makes for great press to claim the cost of a treatment is outrageous, until you use your brain and look at why. I for one hope companies continue to brave their own money is search of these wonder drugs.
particularly Sovaldi from Gillead which cures Hepatitus C for $84,000. And here is MDVN charging $84,000 for Xtandi treatment that doesn't cure anything.
Revenues driven by recent contracts for the most advanced life saving diagnostics will expand 150 times in the next 24 months. And that is just the beginning!
Millennium Healthcare (MHCC) recently announced newly SIGNED contracts with ACO’s IPA’s and MSO’s to provide exclusive, state-of-the-art, non-invasive cardiovascular and cancer diagnostics to 1,300 locations that will escalate Millennium’s current revenues of $2 million per year to over $300 million per year.
Cardiovascular and cancer diagnostics rolling out to physician’s offices this year.
Revenues will begin rapid growth by year end.
Market size for Millennium Diagnostics is 35,000 primary care offices. The first 1,300 recently contracted with Millennium and the rest are standing in line to sign up with Millennium because:
§ Millenniums program increases physician’s revenues dramatically
§ Millennium’s diagnostics are fully paid by Medicare and are free to patients
§ Millennium’s diagnostics appeal to patients because they are life-saving, fast, painless and highly accurate
§ Millennium’s diagnostics are exclusive from Millennium only
§ The physician pays no up front capital costs
Millennium’s market cap is under $40 million today and shares are selling at under $1.00.
What will this growth do to the price of MHCC shares?
Millennium HealthCare is well positioned for explosive growth that is rarely seen.
Sentiment: Strong Buy
On the other hand, the last time you posted this nonsense, on May 13, the stock was at 66.